#China #Hangzhou #Lynk Pharmaceuticals #LNK01004 #Vitlago Treatment

Lynk Pharmaceuticals Marks a Milestone in Vitiligo Treatment with Phase II Clinical Trial

Lynk Pharmaceuticals Co., Ltd., a prominent player in the field of drug development focused on immune and inflammatory diseases, has recently achieved a critical milestone in its clinical research. On June 30, 2026, the company announced that the first patient has been successfully dosed in a Phase II clinical trial evaluating its novel drug candidate, LNK01004 ointment, aimed at treating vitiligo.

Vitiligo is a long-term skin condition that causes patches of skin to lose their pigment. This not only affects the physical appearance of those suffering from the condition but has also been linked to psychological and social challenges. The need for innovative treatments has never been more pressing.

The Phase II trial represents a randomized, double-blind, vehicle-controlled study designed to thoroughly assess the efficacy and safety of LNK01004 when applied topically to adult patients with vitiligo. The research is being conducted under the expert guidance of Professor Jianzhong Zhang and Professor Cheng Zhou, dermatologists from Peking University People's Hospital, at multiple research centers across China.

LNK01004 ointment stands out as a soft pan-JAK inhibitor, demonstrating the potential to become a pioneering therapy for conditions related to inflammatory cytokines. What sets this treatment apart is its low systemic exposure coupled with skin-restricted distribution, which aims to deliver effective treatment directly to the affected areas while minimizing side effects commonly associated with systemic therapies. This makes LNK01004 a promising candidate for patients who require a balance between efficacy and safety.

Previous studies — both preclinical and clinical — have shown that LNK01004 exhibits encouraging results in terms of efficacy and safety. In addition to vitiligo, Lynk Pharmaceuticals is also advancing this innovative treatment for other inflammatory skin issues such as chronic hand eczema, widening its dermatological pipeline.

Dr. Henry Wu, who oversees the clinical research program at Lynk, commented on the significance of their findings. He stated, “Patients dealing with vitiligo not only face the persistent physical challenge of skin depigmentation but also endure long-lasting psychological and social difficulties. LNK01004 features a state-of-the-art, skin-restricted molecular design that retains robust pan-JAK inhibitory action while limiting systemic drug exposure. We are eager to evaluate its efficacy and safety further in this clinical trial, thereby generating solid clinical evidence to support future pivotal trials.”

Lynk Pharmaceuticals is helmed by Dr. Zhao-Kui (ZK) Wan, the Founder, Chairman, and CEO, who emphasized the importance of LNK01004 within the company’s portfolio of innovative therapies for immune-mediated inflammatory skin diseases. According to Dr. Wan, “The successful dosing of the first patient in this Phase II trial for vitiligo signifies a major achievement in our clinical development roadmap. With its unique skin-restricted molecular architecture, LNK01004 has the potential to provide a novel treatment alternative for patients, combining efficacy and safety for long-term convenience. We are committed to accelerating this program to bring this transformative therapy to the market as soon as possible.”

Founded by experienced leaders from top pharmaceutical companies like Pfizer and Johnson & Johnson, Lynk Pharmaceuticals is dedicated to addressing unmet clinical needs through first-in-class innovations. Its integrated research and development platform spans target discovery, molecular design, translational research, and clinical development, seeking to develop differentiated therapies for patients worldwide.

In conclusion, the successful dosing of the first patient in Lynk Pharmaceuticals' clinical trial marks a pivotal step in the advancement of vitiligo treatment options. As they push the boundaries of what's possible in dermatology, the implications for improved patient quality of life are profound. The active development of LNK01004 reflects the company's commitment to innovation and improving treatments for chronic skin conditions.